Baidu
map

传统中药打破肿瘤治疗困境 开创新时代

2017-10-18 佚名 医师报

近年来,肿瘤治疗快速发展,化疗、内分泌治疗、免疫治疗、基因治疗等均取得了长足进步,各种新药层出不穷。然而,近日《英国医学杂志(BMJ)》发表的一篇文章揭示,2009-2013年欧洲药品管理局(EMA)批准了几十种癌症药物,这些新药费用昂贵,但近半数不能改善患者生存。实际上,此前也有类似报道。2016年JAMA Oncology上发表的一篇文章也显示,2003-2013年欧美批准的癌症药物中,约


近年来,肿瘤治疗快速发展,化疗、内分泌治疗、免疫治疗、基因治疗等均取得了长足进步,各种新药层出不穷。然而,近日《英国医学杂志(BMJ)》发表的一篇文章揭示,2009-2013年欧洲药品管理局(EMA)批准了几十种癌症药物,这些新药费用昂贵,但近半数不能改善患者生存。实际上,此前也有类似报道。2016年JAMA Oncology上发表的一篇文章也显示,2003-2013年欧美批准的癌症药物中,约1/5对患者无益。癌症药物似乎走入了困境,面对日益高发的癌症人群,未来癌症治疗又该何去何从?

中医药作为我国传统文化之瑰宝,在癌症治疗中也发挥着举足轻重的作用。然而,中医药的治疗效果常受到质疑,特别是在循证医学的时代大背景下,中医药治疗癌症常被认为缺乏“科学证据”。因此,用现代化的方法进行科学研究是传统中医药的必然之路。

复方苦参注射液(岩舒)作为中医药国际化之路上的先锋,已取得了令人瞩目的成绩,在国内外高影响因子杂志上发表了多篇机制和临床研究,特别是刊登在《肿瘤靶标(Oncotarget)》的研究结果,阐述了使用中药治疗癌症的复杂机制,证实了复方苦参在杀死癌症细胞方面的效果,引起了国内外对中医药治疗癌症的广泛关注。

科学研究:揭秘传统中药如何杀死癌细胞

复方苦参注射液是中国国家中医药管理局认可的中成药配方,被广泛用于多种癌症的临床治疗。所含药物由苦参和白土苓根部提取,苦参碱与氧化苦参碱是其中的主要化合物。虽然大量经验证实了其效果,但抗癌原理尚未得知。

2012年,澳大利亚阿德莱德大学和山西中医学院的研究者开始对复方苦参注射液进行机制探索,首次描述了传统中药的分子作用,而不是将其分解成其组成部分。

研究使用人乳腺癌细胞系MCF-7作为体外研究对象,利用RNA-seq技术测定复方苦参注射液作用后癌细胞基因水平的变化。研究以两种不同剂量的复方苦参注射液(总生物碱含量1 mg/ml、2 mg/ml)为试验组,采用5-FU作为对照组,同时测定孵育24 h和48 h后对细胞增殖与凋亡的影响。

结果显示,由复方苦参注射液触发的基因表达模式与化疗药物5-FU影响的生物学通路一致,改变了细胞周期的调控方式,抑制了MCF-7人乳腺癌细胞的增殖,还可能通过p53的独立机制来诱导乳腺癌细胞凋亡。多途径干扰和细胞周期阻滞是复方苦参注射液在乳腺癌细胞中的潜在靶向途径。

澳大利亚阿德莱德大学David Adelson教授表示,复方苦参注射液可以抑制乳腺癌细胞增殖并诱导其凋亡。复方苦参注射液诱发的基因表达模式可影响与西方化疗相同的通路,但是作用于同一通路中的不同基因。这些基因调节着细胞分裂周期和死亡,并且CKI改变了细胞周期被调控的方式,将癌细胞推向细胞死亡途径,从而杀死细胞。

专家观点:开拓中药国际化之路

中国医学科学院肿瘤医院孙燕院士:复方苦参注射液能够进入医保目录中药抗肿瘤药目录,特别是作为治疗药物而不是辅助药物出现,十分不易。希望对复方苦参注射液还要做更深入的研究,如与曲马多、氨酚待因等镇痛药为对照药做抑制癌性疼痛的临床研究;在抗肿瘤研究方面,要做肿瘤分型研究,甚至细胞因子水平的研究;既然临床发现复方苦参注射液在治疗头颈部肿瘤放疗引起口咽腔黏膜炎方面有非常好的疗效,那就应该继续深入的研究。这就是创新。

中国医学科学院肿瘤医院石远凯教授:中医药的传承一定离不开临床研究,如复方苦参注射液已经在国内进行了多项临床研究,并与国际研究机构展开了多项基础研究项目,取得了令人瞩目的成果。这是中医药发展可借鉴的模式,振东作为中药企业,在这方面勇于开拓,不断探索,因此也成为了该领域的创新典范。

全军中医药研究所、解放军302医院肖小河教授:早于20多前,复方苦参注射液已被批准用于治疗癌症。研究证明,该药不仅可以阻止TRPV1通道发出信号直接抑制癌痛,还可以通过降低肿瘤生长速度间接缓解癌痛。此外,临床观察证实,与单独化疗相比,采用复方苦参注射液作为辅助药物能够有效提高疼痛总缓解率和生活质量,减轻化疗给患者带来的不良反应。

解放军总医院白莉教授:复方苦参注射液在提高消化道恶性肿瘤患者机体免疫力方面帮助较大,在控制中晚期患者癌痛方面作用明确且不良反应少,在其他症状改善方面也功效卓越,是临床医生在恶性肿瘤患者治疗时重点使用的一种优质中药注射液。

北京中医药大学东方医院胡凯文教授:肿瘤用药需辨证,分清寒热。复方苦参注射液为复方制剂,由苦参和白土苓两味中药组成,苦参性寒,白土苓性平,两药相合其性味偏寒凉,因此在临床上用于治疗恶性肿瘤,疗效明显。

全军肿瘤内科诊断治疗中心于忠和教授:中西医联合治疗常可发挥一加一大于二的效果。如复方苦参注射液不仅可以有效缓解癌痛,还可让放疗、化疗增敏,同时还充分调动了患者机体的细胞、体液等免疫力以抑制肿瘤细胞的增殖,使患者机体达到一种平衡状态,进而达到减少癌症复发与转移的目的。

解放军总医院张欣欣教授:复方苦参注射液有扎实的基础研究,不仅有抗自由基的作用,还具有抗癌、镇痛的作用,其联合西药治疗放化疗引起的口腔黏膜损伤的疗效非常显著。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707209, encodeId=616e1e07209ef, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Oct 21 16:45:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285440, encodeId=ede11285440dc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304069, encodeId=193a130406932, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582625, encodeId=fd59158262513, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254205, encodeId=7ea5254205ec, content=有点意思.认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo61WAV0ROeLAoicPxPKoKaogwLWLL8STv86qplbdOibN2YR4KxkJicqNectCXGR8gPJhGLc7yYLSdnpx4kaVXndTfu/0, createdBy=a6962042337, createdName=1391e9f2a7m, createdTime=Thu Oct 19 07:11:22 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254115, encodeId=8f012541154a, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:39:47 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1707209, encodeId=616e1e07209ef, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Oct 21 16:45:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285440, encodeId=ede11285440dc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304069, encodeId=193a130406932, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582625, encodeId=fd59158262513, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254205, encodeId=7ea5254205ec, content=有点意思.认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo61WAV0ROeLAoicPxPKoKaogwLWLL8STv86qplbdOibN2YR4KxkJicqNectCXGR8gPJhGLc7yYLSdnpx4kaVXndTfu/0, createdBy=a6962042337, createdName=1391e9f2a7m, createdTime=Thu Oct 19 07:11:22 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254115, encodeId=8f012541154a, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:39:47 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1707209, encodeId=616e1e07209ef, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Oct 21 16:45:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285440, encodeId=ede11285440dc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304069, encodeId=193a130406932, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582625, encodeId=fd59158262513, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254205, encodeId=7ea5254205ec, content=有点意思.认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo61WAV0ROeLAoicPxPKoKaogwLWLL8STv86qplbdOibN2YR4KxkJicqNectCXGR8gPJhGLc7yYLSdnpx4kaVXndTfu/0, createdBy=a6962042337, createdName=1391e9f2a7m, createdTime=Thu Oct 19 07:11:22 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254115, encodeId=8f012541154a, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:39:47 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1707209, encodeId=616e1e07209ef, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Oct 21 16:45:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285440, encodeId=ede11285440dc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304069, encodeId=193a130406932, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582625, encodeId=fd59158262513, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254205, encodeId=7ea5254205ec, content=有点意思.认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo61WAV0ROeLAoicPxPKoKaogwLWLL8STv86qplbdOibN2YR4KxkJicqNectCXGR8gPJhGLc7yYLSdnpx4kaVXndTfu/0, createdBy=a6962042337, createdName=1391e9f2a7m, createdTime=Thu Oct 19 07:11:22 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254115, encodeId=8f012541154a, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:39:47 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1707209, encodeId=616e1e07209ef, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Oct 21 16:45:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285440, encodeId=ede11285440dc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304069, encodeId=193a130406932, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582625, encodeId=fd59158262513, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254205, encodeId=7ea5254205ec, content=有点意思.认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo61WAV0ROeLAoicPxPKoKaogwLWLL8STv86qplbdOibN2YR4KxkJicqNectCXGR8gPJhGLc7yYLSdnpx4kaVXndTfu/0, createdBy=a6962042337, createdName=1391e9f2a7m, createdTime=Thu Oct 19 07:11:22 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254115, encodeId=8f012541154a, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:39:47 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-19 1391e9f2a7m

    有点意思.认真学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1707209, encodeId=616e1e07209ef, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Oct 21 16:45:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285440, encodeId=ede11285440dc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304069, encodeId=193a130406932, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582625, encodeId=fd59158262513, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 20 10:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254205, encodeId=7ea5254205ec, content=有点意思.认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo61WAV0ROeLAoicPxPKoKaogwLWLL8STv86qplbdOibN2YR4KxkJicqNectCXGR8gPJhGLc7yYLSdnpx4kaVXndTfu/0, createdBy=a6962042337, createdName=1391e9f2a7m, createdTime=Thu Oct 19 07:11:22 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254115, encodeId=8f012541154a, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:39:47 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 惠映实验室

    学习了.谢谢.

    0

Baidu
map
Baidu
map
Baidu
map